Pfizer Inc. (NYSE:PFE) Shares Sold by Brown Advisory Inc.

Brown Advisory Inc. lowered its position in Pfizer Inc. (NYSE:PFE - Free Report) by 11.1% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 937,289 shares of the biopharmaceutical company's stock after selling 117,326 shares during the period. Brown Advisory Inc.'s holdings in Pfizer were worth $23,751,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC increased its position in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC raised its stake in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after purchasing an additional 2,087 shares during the last quarter. AlphaQuest LLC lifted its holdings in Pfizer by 26.1% in the 4th quarter. AlphaQuest LLC now owns 24,083 shares of the biopharmaceutical company's stock valued at $639,000 after purchasing an additional 4,987 shares in the last quarter. Sage Mountain Advisors LLC boosted its stake in shares of Pfizer by 7.3% during the 4th quarter. Sage Mountain Advisors LLC now owns 20,587 shares of the biopharmaceutical company's stock worth $546,000 after purchasing an additional 1,404 shares during the last quarter. Finally, Donaldson Capital Management LLC grew its holdings in shares of Pfizer by 1.2% during the fourth quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company's stock worth $947,000 after buying an additional 410 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Down 0.5%

Shares of NYSE PFE traded down $0.13 during trading on Friday, reaching $25.65. 34,838,317 shares of the stock were exchanged, compared to its average volume of 41,792,724. The company has a market capitalization of $145.83 billion, a price-to-earnings ratio of 18.59, a price-to-earnings-growth ratio of 0.94 and a beta of 0.58. The business's 50-day moving average price is $23.89 and its 200 day moving average price is $24.80. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same period in the prior year, the company posted $0.82 EPS. The firm's revenue for the quarter was down 7.8% on a year-over-year basis. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.71%. The ex-dividend date is Friday, July 25th. Pfizer's payout ratio is currently 124.64%.

Analyst Ratings Changes

Several analysts have commented on the stock. The Goldman Sachs Group lifted their target price on shares of Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Redburn Atlantic decreased their price objective on Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. Berenberg Bank lowered their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. BMO Capital Markets reduced their target price on Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. Finally, Wolfe Research lifted their price target on Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Pfizer has a consensus rating of "Hold" and a consensus target price of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.